0001104659-23-128782.txt : 20231222 0001104659-23-128782.hdr.sgml : 20231222 20231222160112 ACCESSION NUMBER: 0001104659-23-128782 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231220 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Barinthus Biotherapeutics plc. CENTRAL INDEX KEY: 0001828185 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40367 FILM NUMBER: 231509699 BUSINESS ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF BUSINESS PHONE: 44 (0) 1865 818808 MAIL ADDRESS: STREET 1: UNIT 6-10, ZEUS BUILDING STREET 2: RUTHERFORD AVENUE, HARWELL CITY: DIDCOT STATE: X0 ZIP: OX11 0DF FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech plc DATE OF NAME CHANGE: 20210407 FORMER COMPANY: FORMER CONFORMED NAME: Vaccitech Ltd DATE OF NAME CHANGE: 20201014 8-K 1 tm2333622d1_8k.htm FORM 8-K
false 0001828185 00-0000000 0001828185 2023-12-20 2023-12-20 0001828185 BRNS:AmericanDepositarySharesMember 2023-12-20 2023-12-20 0001828185 us-gaap:CommonStockMember 2023-12-20 2023-12-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 20, 2023

 

BARINTHUS BIOTHERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

 

England and Wales 001-40367 Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

Barinthus Biotherapeutics plc

Unit 6-10, Zeus Building Rutherford Avenue,

Harwell, Didcot, OX11 0DF

United Kingdom

(Address of principal executive offices, including zip code)

 

+44 (0) 1865 818 808

(Registrant’s telephone number, including area code)

  

 Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trade Symbol(s) Name of each exchange on which
registered
American Depositary Shares BRNS The Nasdaq Global Market
Ordinary shares, nominal value £0.000025 per share*    

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

 

 

 

 

   

Item 1.01. Entry into a Material Definitive Agreement.

 

On December 20, 2023, Barinthus Biotherapeutics plc (the “Company”), the Chancellors, Masters and Scholars of the University of Oxford (“Oxford,” together with the Company, the “Partners”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) entered into a Funding Agreement (the “Funding Agreement”) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company’s vaccine candidate against Middle East Respiratory Syndrome (“MERS,” and such development activities, the “Project”). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. Under the Funding Agreement, the Partners have agreed to use reasonable endeavors to achieve the deliverables, milestones and timelines for the vaccine development activities under discrete “Work Packages” mutually agreed to by the parties from time to time.

 

Under the initial Work Package, the Company has agreed, subject to the achievement of certain milestones, including a successful Phase II clinical trial of VTP-500, that it will manufacture or have manufactured an investigational ready reserve of 100,000 doses of VTP-500 to be rapidly deployed for a clinical trial in the event of a substantial outbreak of MERS. During the Term (as defined below), the Company has also agreed to certain collaboration obligations in the event of a regional or national public health emergency or preparation need for an impending outbreak of MERS.

 

Pursuant to the Funding Agreement, the Company will retain ownership of its intellectual property owned or controlled throughout the term of the Funding Agreement, subject to the rights of CEPI under the Funding Agreement. The Company will also own any intellectual property invented by or on behalf of the Company in connection with the activities contemplated by the Funding Agreement, as well as all tangible materials and results made or developed by or on behalf of the Company in connection with the Funding Agreement.

 

Any amounts funded by CEPI to the Partners under the Funding Agreement in accordance with each Work Package will be paid in tranches covering six-month periods based on mutually agreed project-based budgets and subject to certain conditions as set forth in the Funding Agreement including the achievement of identified milestones.

 

Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (“Effective Date”) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (10th) anniversary of the first commercial sale of VTP-500 (the “Royalty Term”). The Company shall also pay CEPI a mid-double digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries (“LMICs”) and upper and middle income countries (“UMICs”) are excluded from the calculations of net sales and net revenue. Sales of product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a mid-double digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.

 

The Funding Agreement will commence on the Effective Date and will continue until the fifth (5th) anniversary of the Effective Date, unless the parties agree to extend the Funding Agreement for a period of up to twenty-four (24) months unless all activities under the Funding Agreement have been completed (“Term”). Either Partner or CEPI can terminate the Funding Agreement following an insolvency event or material breach by the other party that is not cured within forty-five (45) business days, in the event of termination by a Partner, or thirty (30) business days, in the event of termination by CEPI. Pursuant to the Funding Agreement, CEPI also has certain discretionary termination rights, including if CEPI determines that the Company is involved in material safety, regulatory, scientific misconduct, or ethical issues or is no longer able to fulfill its obligations under the Funding Agreement.

 

Neither CEPI, the Company nor Oxford may assign its rights or obligations under the Funding Agreement without the other parties’ consent; provided that CEPI may do so to an organization of equivalent charitable mission and technical capabilities.

 

 

 

 

The foregoing description of the material terms of the Funding Agreement does not purport to be complete and is qualified in its entirety by reference to such agreement, which will be filed with the Securities and Exchange Commission (the “SEC”) as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

 

Item 7.01. Regulation FD Disclosure.

 

On December 21, 2023, the Company issued a joint press release with Oxford and CEPI titled “New partnership aims to advance emergency vaccine against MERS coronavirus.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

  

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release, dated December 21, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

  

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Barinthus Biotherapeutics plc
     
Date: December 22, 2023 By: /s/ William Enright
    William Enright
    Chief Executive Officer

  

 

 

 EX-99.1 2 tm2333622d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

New partnership aims to advance vaccine against MERS coronavirus

 

Dec 21, 2023

 

·CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500.
·VTP-500 project with Barinthus Bio and University of Oxford uses tested ChAdOx1 platform.
·If successful in Phase II trials, this will progress VTP-500 significantly towards regulatory approval and doses could be rapidly deployed in a clinical trial setting in response to a substantial outbreak.

 

OXFORD, United Kingdom, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced a project with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford, aiming to fast-track the development of a vaccine candidate known as VTP-500 for the prevention of Middle East Respiratory Syndrome (MERS), the often fatal disease caused by the MERS coronavirus. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

 

The project will see CEPI, Barinthus Bio, an Oxfordshire-based clinical-stage biopharmaceutical company, and the University of Oxford together take a MERS vaccine from early development through Phase II clinical trials and, if the Phase II clinical trials are successful, on into the development of an investigational ready reserve1 of 100,000 doses to be rapidly deployed in a clinical trial setting in the event of a substantial outbreak.

 

“Coronaviruses are one of the most urgent infectious disease threats the world faces, so it’s vital that we get on with developing medical defences against this particularly deadly one – MERS,” said Dr Richard Hatchett, CEPI’s Chief Executive Officer. “With this project, we will both advance scientific understanding of the coronavirus family as a whole, and at the same time bolster humanity’s ability to respond to an ever-present epidemic threat.”

 

“The COVID-19 pandemic showed us the critical importance of vaccines in saving millions of lives around the world,” said Professor Dame Sarah Gilbert, Pandemic Sciences Institute, University of Oxford. “We had a head-start in our development of the Oxford/AstraZeneca COVID-19 vaccine, thanks to the many years already spent researching a vaccine for another coronavirus, MERS. This new partnership will help ensure the world is better prepared with vaccines for future outbreaks.”

 

“We are thrilled to be working with the University of Oxford and CEPI on the development of this important vaccine candidate,” said Bill Enright, Barinthus Bio’s Chief Executive Officer. “There is an active need for a MERS vaccine for at-risk populations and travellers in the Middle East. As we observed during the COVID-19 pandemic, it is critical to ensure we have the necessary countermeasures in place to protect people around the world from deadly pathogens such as MERS which have the potential for future outbreaks.”

 

The three-way partnership, which awards up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford, builds on the early-stage development of VTP-500, which is based on the same viral vector platform technology as the licensed Oxford-AstraZeneca COVID-19 vaccine, Vaxzevria. VTP-500 has already completed Phase I clinical trials in Britain and Saudi Arabia, and the University of Oxford is now conducting a CEPI-funded extension to the Phase I trial in the UK to assess vaccination of older adults, the age group most in need of this vaccine. The VTP-500 programme was awarded PRIME designation earlier in December by the European Medicines Agency (EMA).

 

MERS is a severe respiratory infection caused by MERS-CoV, a coronavirus that was first identified in 2012 in Saudi Arabia. It has caused more than 2,600 human infections in at least 27 countries since it first emerged, and it has a case-fatality rate of more than 35 percent. There are as yet no licensed vaccines or treatments for MERS.

 

Enabling equitable access to VTP-500

 

CEPI, the University of Oxford and Barinthus Bio are committed to enabling equitable access to VTP-500 in line with CEPI’s Equitable Access Policy so the vaccine is first available to populations when and where it is needed to end an outbreak or curtail an epidemic, regardless of ability to pay. If the vaccine is successful in Phase II trials, CEPI will support production of an investigational ready reserve of 100,000 doses which can be rapidly deployed in a clinical trial setting in response to an outbreak of MERS. CEPI also has the ability to support technology transfer to an additional appropriate regional manufacturer to enable supply for low- and middle-income countries. The vaccine will be made available to low- and middle- income countries at a price no higher than the cost of manufacturing plus 10 percent.

 

 

1 An investigational ready reserve is an agreed quantity of investigational doses for potential use in a clinical trial.

 

 

 

 

Notes to Editors

 

EMA PRIME Designation

 

Due to VTP-500’s potential in significantly addressing the unmet need for MERS, the EMA has confirmed support for the program through the PRIME designation. PRIME enhances support for the development of medicines that target an unmet medical need, offering early and proactive support to medicine developers to optimise the generation of robust data on a medicine's benefits and risks and enable accelerated assessment of medicines applications.

 

Emergency Use

 

The agreement refers to supply in Outbreaks defined as a Public Health Emergency of International Concern declared by WHO, or a public health emergency on a national or regional scale declared by one or more public health agencies.

 

About CEPI

 

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.

 

CEPI has supported the development of over 30 vaccine candidates against its priority pathogens—Chikungunya virus, Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and SARS-CoV-2—and is a leading funder of research into broadly protective coronavirus vaccines, which could protect against future variants of COVID-19 as well as other coronaviruses with epidemic and pandemic potential. The organization has also invested in the development of rapid response platforms to develop vaccines against Disease X (the threat of an unknown virus).

 

CEPI has contributed to a number of scientific breakthroughs, including the first Phase 3 trial of a Chikungunya vaccine and the advancement of the first ever Nipah and Lassa vaccines into Phase I trials. The organization played a central role in the global response to COVID-19, supporting the development of one of the world’s largest portfolios of vaccines against SARS-CoV-2, seven of which have been approved for domestic or global use. It also co-led COVAX, the global initiative to deliver fair and equitable access to COVID-19 vaccines, which has delivered approximately 2 billion doses of vaccine to 146 countries around the world.

 

CEPI’s five-year plan for 2022-2026 aims to dramatically reduce or even eliminate the future risk of pandemics and epidemics. Central to the plan is CEPI’s goal to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Achieving this ‘100 Days Mission’, which has been embraced by the G7 and G20, would give the world a fighting chance of containing a future outbreak before it can spread to become a global pandemic.

 

Visit our news page for the latest updates. Follow us via @CEPIvaccines, @DrRHatchett, LinkedIn, and Facebook.

 

 

 

 

About Barinthus Biotherapeutics

 

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP; Barinthus Bio is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-Tolerance Immunotherapy (TI) platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-Cancer Immunotherapy (CI) platform to treat patients with HPV-related cancer. Barinthus Bio’s proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives. For more information, visit www.barinthusbio.com.

 

Barinthus Bio Forward-Looking Statements

 

This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “may,” “will,” “plan,” “forward,” “encouraging,” “believe,” “potential,”

 

and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding the Company’s future expectations, plans and prospects, including the potential benefits of VTP-500 for the treatment of MERS. Any forward-looking statements in this press release are based on Barinthus Bio management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of Barinthus Bio’s pipeline development activities and planned and ongoing clinical trials, Barinthus Bio’s ability to execute on its strategy, regulatory developments, the risk that Barinthus Bio may not realize the benefits related to its rebranding and name change, Barinthus Bio’s ability to fund its operations and access capital, global economic uncertainty, including disruptions in the banking industry, the conflict in Ukraine, and the conflict in Israel and Gaza, and other risks identified in Barinthus Bio’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports on Form 10-Q and subsequent filings with the SEC. Barinthus Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Barinthus Bio expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

About Pandemic Science Institute, University of Oxford

 

The Pandemic Sciences Institute at the University of Oxford is a research institute with a mission to discover, create and enable practical solutions to infectious disease threats worldwide. The Institute is hosted by the University’s Nuffield Department of Medicine. Visit our website and Follow us on X (formerly Twitter).

 

 

 

 

Media contacts

 

CEPI

E: press@cepi.net

T: +44 7387 055214

 

Barinthus Biotherapeutics

Investor Contacts:

Christopher M. Calabrese

Managing Director

LifeSci Advisors

+1 917-680-5608

ccalabrese@lifesciadvisors.com

 

Kevin Gardner

Managing Director

LifeSci Advisors

+1 617-283-2856

kgardner@lifesciadvisors.com

 

Media contact:

Audra Friis

Sam Brown, Inc.

+1 917-519-9577

audrafriis@sambrown.com

 

Company contact:

Jonothan Blackbourn

IR & PR Manager

Barinthus Biotherapeutics

ir@barinthusbio.com

 

University of Oxford

E: news.office@admin.ox.ac.uk

T: +44 1865 280528

 

 

 

 EX-101.SCH 3 brns-20231220.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 brns-20231220_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 brns-20231220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] American Depositary Shares[Member] Common Stock [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 brns-20231220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2333622d1_ex99-1img001.jpg GRAPHIC begin 644 tm2333622d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 20, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 20, 2023
Entity File Number 001-40367
Entity Registrant Name BARINTHUS BIOTHERAPEUTICS PLC
Entity Central Index Key 0001828185
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Barinthus Biotherapeutics plc
Entity Address, Address Line Two Unit 6-10
Entity Address, Address Line Three Zeus Building Rutherford Avenue
Entity Address, City or Town Harwell, Didcot
Entity Address, Country GB
Entity Address, Postal Zip Code OX11 0DF
City Area Code +44 (0)
Local Phone Number 1865 818 808
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
American Depositary Shares[Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares
Trading Symbol BRNS
Security Exchange Name NASDAQ
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.000025 per share*
XML 9 tm2333622d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001828185 2023-12-20 2023-12-20 0001828185 BRNS:AmericanDepositarySharesMember 2023-12-20 2023-12-20 0001828185 us-gaap:CommonStockMember 2023-12-20 2023-12-20 iso4217:USD shares iso4217:USD shares false 0001828185 00-0000000 8-K 2023-12-20 BARINTHUS BIOTHERAPEUTICS PLC X0 001-40367 Barinthus Biotherapeutics plc Unit 6-10 Zeus Building Rutherford Avenue Harwell, Didcot OX11 0DF GB +44 (0) 1865 818 808 false false false false American Depositary Shares BRNS NASDAQ Ordinary shares, nominal value £0.000025 per share* true false 00-0000000 EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 25 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vaccitech.co.uk/role/Cover Cover Cover 1 false false All Reports Book All Reports brns-20231220.xsd brns-20231220_def.xml brns-20231220_lab.xml brns-20231220_pre.xml tm2333622d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333622d1_8k.htm": { "nsprefix": "BRNS", "nsuri": "http://vaccitech.co.uk/20231220", "dts": { "schema": { "local": [ "brns-20231220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "brns-20231220_def.xml" ] }, "labelLink": { "local": [ "brns-20231220_lab.xml" ] }, "presentationLink": { "local": [ "brns-20231220_pre.xml" ] }, "inline": { "local": [ "tm2333622d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://vaccitech.co.uk/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333622d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333622d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "BRNS_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://vaccitech.co.uk/20231220", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares[Member]", "documentation": "American Depositary Shares" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://vaccitech.co.uk/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-128782-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-128782-xbrl.zip M4$L#!!0 ( "6 EE> 2[XPM@, /<- 1 8G)NM7SNVP4RZ&Q?:29--AEG2=B%MT[YT9%F !EMR=0FP MO[Y'O@4P$*"-G^1SON]LZGD7LQ MNNSW'?3VS8L_$'S=/UT773.:Q"&Z$L3M\[%XC=[CE(;HAG(JL1;R-?J,$V,E MXIHE5*)+D68)U104A:<0G7E!BR#7/<#N9\IC(3\-^[7=J=:9"GU_/I][7#S@ MN9 SY1&1'F9PI+$VJK;66K3*[S#Z+5.D)K_$%V?SOQ9#=C^A_&\SP)UOY N^ MO FB#_'_WX8O1U]G"YV^.X^B]-7]\G9F[O[#>&ENYO^>!9/[K_\4+KN*3&F* M$1P&5SW'YE>F-^]X0D[\H-5J^_>W@U&.)- MQ(,/"L 'G0IHE#O!.*O!8ZRBW&BI6 ,KJ9M $&Z"7+W,J-H*+51KA%C+#<+: MKH':MVK+"=Q6Q^VT*^:[X?M137K A#!-R13*V3.SW$4[".RU3&A*N;X6,KVB M8VP2R.*'P0D;,QH[2&,YH=I6J,HPH4\;K"H=K%Z_U) 8W$0BWM.L5RQ5UF,Z9AQEGLO+V$;N?;*&9LL M+'-FU]\$-RT91>,/_$V^SB150,^S&H"@Y)>0_5R"$V*2DZB/\>UCEO)J+QN; M7-W%(1VC_ Z'MG!ZCF*VBSJE;"KIN.=$DBNW.M+OD+8'-55!K(<]=S@_H\V= M*AU7)K D#2N-'@-&1$:E9G E5AI)$3K3EOYQQ0VR?I2#_-^8>8*C8S,'"DV> M,>6!M?\F$^4\)7M9-FUEU_O:7 _V;;Z4+B0FK$&RULW_-3/)P# M07)3>RCVSZUXKA6Y[0"ZL+=0\6.DQP3QN W'!5'Q3@ABQR.XS;_:!;>+O)@. M=;KC,=WK="O'IXE6E>3D$%:?WE^((3=S5!!/O^>[PGF*F?^KDXJ ",.U7!Y3 M"*N4ZN>TTW@T(5-)WO+(%RU,HG%SN=?;](J60$\RN: M"<5@U%J.IAB>M%N:1G;$L<'VG*=0.%):8@)SFY8&V@9G"3Q"MG46__G0'4*7 M92*^RQ^#V,@\)QCOBO]JR QCD6+&^YJF%@E[8, XT\:B;Z0P, L7YF J2XO4 MNGZQ4;#\"5!+ P04 " E@)97^CIIO.P( "T:0 %0 &)R;G,M,C R M,S$R,C!?9&5F+GAM;-5=75/C.!9]WZK]#Y[L?(DJXEF8^_;F,:/&,A M"6?G@_'1\2# +.018:OSP1_SX<5\.IL- JD0BQ#E#)\/&!_\^H^__B70_S[^ M,!P&-P33Z"RXXN%PQI;\E^ +BO%9\!MF6"#%Q2_!5T03N'B21R&/ M^Q4X5T@EY?Z2$/9V9'PLD<:#Y8O)L*\GYP-2;5_MR)E2;'[C#Q\^C-)O"].&Y78A:%''R:B LR]9 M?QNIO4/9^'24?5DV)2U%ET!+!F8_[70^UJ?41@2A<.U%O1J9[T=3KINO!IMZK@5> MG@\6@DE=P>1D/)D5K780(DP4>1B3&S+3X09!75 YO7PIA:J1-1[G-R%K ^^/>5S:,>(S(@:"; MW@X0IS4-8QPOC-P'P:VZOC]61.EA"%.']\?%N+HX%%KAX[1-XB5*J/KF1EFX M5S'KRX01T]=]TK]6<..MTD,/C@KDIL #NB9%E+'/QY9Q,#0#4:+A*/TQL\R1 M%%@H#RL J.F%N6@R)XN0)0Z/5OQY%&$R,OV?^9!VA!EWF#P6=9H!4,0H#Q3/ M%(YE43!%"TS3ZAZU2[O'Z'_&O$1RD6J5R.$*H4T&'%,EBRNO$>07'LV0C0VH M![1X;4HEW+EAW:Z.]E7M"U'@SIM*S_LQ:Y]G(6=*MX]KFM:FVSA>F0\%LJ7@ M<4]"<_)X:QQEAC6<0OQV_(J)KG7U (BA6BUK?2Y4*7#"## MO!,Y),7DV$\M'L<6X&\E1S%"'MK'O9E>:7209"??*EDS.[B\_S)_O(BQ("%B M5WC#)5%([.9K)+#\G,\(&Z(8KW:G=U"G.DL%F&]I^?P@[&#/]?VZ+A['G*61 M@<(4+-1-'VUW^?^%'*V(P3[K343H/V5\T"6V3Q&-Q>./CDD^<$9E@PLQ_":# M0C?!^D9DD0%T0]'*SG#%Q .*FWC?=1)T ,=76(:";%1IP@=07;+TB?$Z;+#[ M<-M[W.,5D4JD<>QG!NW=B=7% RFZ\8-S&K>:7#"6('JOQW_1(479TB,%&K A MXG]T2_P_$R04%G37A_N:L4?TVY!#"IPZGLP(I+,<$T@?">K6'FE@A0Z)\)-; M$>9K3*E9#42LUYW0M/=(" \),7?OY\4U\]F&J''J_YJ[%T\%:2*']+D9[>: MW.G\G$=ZYB!ZJ%$S]D@'&W)(@0_?0X%K%O7E/S?UCOTR[K;%!9?DWQ 9(IKA MN]'7.M:G&N8>B6#'_KY/WPX5XM\8B=XR[(V]$Z&*')3 4?8\382H0&OMBR!K M#T1HA0ZJX"A?OF:*J)W9O/8E 9XY:[.ZE0>L6R&#;#M*DC-0Q<,3ILPNO3;& MJY;>L&Z!#3+O*#G.@$UU) +1&8OP]G>\:Z.^9NH-]S;<(/F.DN(,V9T@L5F) M(V%W5U.W]89^*W"0?T>9< ;M 6UGD8Z'+$FVY;5;!L#%&S7:\(.B.$J%,X0S M%G*QX:4GZ5.>Z#MX-^51Z]#0ZNB-0-U1@#(YRI>.R"Q]4Z ,&V3>:8J= [OC4B'Z'[+IFL?:['U3H0D>U,)1QIVW"_,@ M!MH,5C'Q@/$F7I!D1VFU&8LN!$9P$R];^$!Q'2[(L*,<^1,W:T=KSEJ?3M>M M/&#:"AEDVU6J:TX!2K##V'_M ;]5K!"QWWS.XD!B_Q1$:3QF#WS"\B=1P%JC MU=0#PF'<(/F.TM4YIR34/+'59SU;%011._--.P]H!T"#G#O*3.\$-BT!ZZ0@ MW:AG#A>+V^42ZL%A>P\TZ /:N$H1:W!FTF98'&H(@TO_W2QAP"JXRA=G>,P MT5WG;CQ9/)A3]$#?5+/R@'TK9)!M1RGJ%_X@D'D!T'P7+SB%#R59##W@'$(- MTNXH&ZV@LA->,?& ZB9>D&1'V6AQPUUOPS5B*PSO+;%9>D Y"!MDWE&6^MK5 MK7KUX2O_^O!5CS[<499:@,H.&NA[\'9!R0K!IQY;'#S2 $(/R6&+[#WDR,ZA ME8*YT1_L0EA-/9 Q@V2[^KH;Q(1A:,,X UAB(4Z!=P?R 2>,71Y^2!)GQ! M=9RNS_Z)*?V=\1*M, '%7&Z63J]::=Z.%OQ]OT+%4-O^&^B!FEWND=Z'B-*+Q.I M Y"M/5+%T!O:FZA!VIWN@KZ.L5CICO$WP5_4.C^XW$:_U<$;&6#TH!Q.=SM? M;U]?K9"=W&S5HF'MCQ!VZ) *IXZ/"5^$H=GTDLT86(0$H -L[X$2'>!!+1RE MV+=JC45YYI9",\&T;4GI\O) EUXA@.HX3;'+K[MH';1+=AXH ( &.7>:0=\E M"TK"&\I1:YY0,O.&\3IFD'"G6?,E8D\BV:AP=R=XB+%9?I+[^[-'RM:K &]$ MZA\-*)_;H\>O+T#-WD5[FZCT3\]HM*V//EK\O!&K,PA0(\>O[9*O!Q)Q=+F[ MQTLLS :2![Q5E[JBI_8)6*>[!XH=%@LH7"EM_SBJA:FK?]+?Y=?-#_-W<_25 M_P)02P,$% @ )8"65Z5[!2\'# -Y$ !4 !B+ M14%+M"-$)@-*3IQ_/_R09(GBD91TAV0O6E=Z#_52?$Q2LGCT_I?M.D5/A&<) MHQ]&!WO[(T1HQ.*$KCZ,/L_&)[.SR\L1RG),8YPR2CZ,*!O]\O-?_X+$G_<_ MC,?H(B%I?(P^LFA\29?L)W2-U^08_4HHX3AG_"?T!:<;N85=)"GAZ(RM'U.2 M$[%#'_@8_;@WW8_0>#R@W"^$QHQ_OKNLRKW/\\?L>#)Y?G[>H^P)/S/^D.U% M;#VLP%F.\TU6E;:_W2_^Z/#W:4(?CN5?"YP1),X7S8ZW6?)A)(];'/;Y<(_Q MU62ZOW\P^?>GJUET3]9XG%!YWB(R*J-D*;:X@Z.CHXG:6TI;RNV"I^4Q#B>E MG:IDL3?IT-><9,EQINQ=L0CGJME[#X- A?S?N)2-Y:;QP71\>+"WS>)1>?+5 M&>0L)7=DB50UC_.71X%2ED@21L6V>TZ6=C,IYQ,9/Z%DA7,2RP,=R0,=_%,> MZ&_%YBN\(.D(2:7@ ZS74:.L(FCBVNPMX0F+S^G;7)O1GNR+[P[/OZ,"]7CG M59BS'*=O,E^/=&[[FKSMC._BW)]IT<^3MYWI6N2?8CMO6W[UZ;6?UU1NO!*? M&A;)-A<#&(E+D[*(CAY8'4$-#$795>DL:I2;RMZ<\7;=Y54;UVLS]*P6#M>IB) 3-D+'GV>CGY4,L2520O152O_W M?K(K^BTL+3C-%" 'T^F^@N3T[GKV[60M.O((TX_DD66)Z,Y?9O=8G(!/9+T@ MW*C0H @7H+S"ND1E@-P[+,,]FKB406@7A7385QWWW>Q\=S\D+AG6C"JG_3$GE'I\]9JW]1NK)W"861JI>6E/5^K*ULQ M^2*7PI0Y6^F7N\!BJ&D)2)_6.RH##9K0E"&H%H.^RBBDPGQ!-!6 M6:76("GRUNNO].V.198Q4% ,\0A.%K4@U 5Y8FC$THW.+T3%\R\"Y^F MS#4U-I,F+'5-4(Q8C(%H:"W28D]$_&N#>4YX^M(+14OIF@O JHF&(0N*#KLW M$)!*[I>1.<;\2<[.Q31I8&5K>I_PM&QW\5.) M@T7(=#B0(A6&9)PGDFK/9_0PU%*ZI@>P:G)CR((BQNX-9$7+D=+[A^26K[\E8#FDECLOV-O(#U:NG<,@'8;$)AB *BPNX,P*(0(Z5&0NX%C%N> MK.43LDG4,U2TA6[1@(PVV3!5 <$!6 /H*-1H=GGF*-=# M":AW"TN/[28S@#@@=+H= @2)(-2,\@G2)8T8?V2UQQW.V$9T@"]G+(9G*#U1 M;J$:5(4F6ITA 0$VQ"> 62/TG7XF!3&YP%D5@&0)7H@[B6-QHK+BGZN$D@.P M_E:M6[HZ[#:9L@@#(@EV!_!3*-^5'Y",038P:&@.WP2-:'BO?$1O"4&9)[ 08P;:7&T(:'CMU@ M'S_5A+B,\]K7Z$EY[Y>DE/GI99HF[5V,UH0'2=-8;^>BU3Z1N&59CM/_)H^= M%^)VL1<\K(:MD#24X:%BL]<'C(Y!(LC'A76!J_Q!P[J4S-CO[-=FFZWJ)^;Z MSB @L#EJ9Q?0=T^TR'4S2T8YP4"/T-SMK)$MIJHVKNT+HXG;AEHMK+[70N/C MBRS3WJ6W]XS"#PBT):Y:&C)7MK:Y/X@6!TR9K:YD2.D\W8V7J;_==V^=L M9#?M5 -YN2.(UC7=M(;I$0/, 2"U]B#A!)GNATH$^V9J1:"/&QY># MZ6*>Y*W\=':)LS$),%>-2,;^(-@ 3)DLJ'TR&>K!].^+?Z RRG'S7[,YQS*K M_NQEO6 ID'W*JG(%08?%D@.+) @48%\F#=<,%5*DM3ZR4S7,6JIC['<%@-56 MV?2-G4$TNLU1Z\O?:&M/7?[Y-KH7I@BP(,$N<]WUVTR:W7]=$P0"'<9:%R6% M%)5:'PL2=D/6JG\2L/(V"5CU3 )6(4X"5D,G 2MODX#RL#I%B.B7;A9ILL) M?JF8NEVC47FSC)2:S-7"04TRC!:94>T79'O#_$&2T# MS5?@].C#8&B8R19..JS,95@%[E)=NKZ5KA_ ^)VDZ6^4/=,9P1FC)-;W4FR_ M%'7KW3XQTV.[^= ,( X"IR$.@4=G9-#X04:A,JRX$^:%I"\LW5#Y=A'U&D!; MSP3HW)(#V&P28X@"(L7N#""D$B.M]K- 6V>/J"99^H6,8 4AN>/EVIVFC57; M5FU S'0:A-9P%SD_=G-C'>5IB65..([RY(E\Q#DNO('UA>2N%U5VF3974]JT M 2'4:1!;+*$D@P6#A?$[X2 MP]NOG#WG]T5^5K!N@-HM&YV6FXQ8I0&QTN4/8*8,03JF3*GK!Y[M+J&XSK(( MU]0B=8P-:-9@IJ4+"1C(7(N6E$3R?LLUR]&?%^WGKF>!U.;[> M-!)%WA*5Y# MY'AF;#%H3(QKBB 8 6U!T^+ZNP+\Y,[;+-(DND@9AN^R-#2.,^:U[1G)\G:" M@ AHNX)2Y"DA4DHO[7^*Z0/?/.;1RRUG$2'R*:NLZJWZ[K\-C';+S*NJU*1I M4&A G+W&+T#@K@A4*^-=;<3R>3.O]B9S_2;[FTV>R1%4&(/O@G<&.?YY84 % MC!\9.B("0F^ 3>@'A]I;Y]\A'8QJT9ZNS[)=%D 2G[[!E?'O)CK#0P"PM>ZA2[U,E0O "WD,V)%$>BK+ 2I4CK?7_XG MM.3IW?5,OIJ7)Q&F'T57G"7RUUW]9?E$S(NH ?)O,8N M/ZR"T"ZJZ#XLK5/?="4^B&ULU5U;4]LX&'W?F?T/ MWNQSR(6]E<)V($ G4UI80MO=?6$46TDTR%)&DB'Y]RO9<4AB2_[H)=+V@0;G M2/K..;+DSY;,\9M%2J-'+"3A[*35.^BV(LQBGA V/6E]'+5/1X/AL!5)A5B" M*&?XI,5XZ\V?/_X0Z7_'/[7;T27!-#F*SGG<'K()?QU]0"D^BMYBA@527+R. M/B&:F2/\DE LH@%/YQ0KK+\H&CZ*?CWH=^.HW0;4^PFSA(N/M\-UO3.EYO*H MTWEZ>CI@_!$]PBH<*:0RN:ZMN^BN_A7%CREA#T?FQQA)'&F]F#Q: M2'+2,NVNFGTZ/.!BVNEWN[W.W^^O1O$,IZA-F-$MQJVRE*FEKESOU:M7G?S; M$EI!+L:"EFT<=LIPUC7K;XD#OQ&))$ MOWW8.UC(I%6*GRLH.,6W>!*9_[5[ZU8?41P3A>.9=NP@>^B8[SL#KOND#C8O M.1-X"H :'_@.V[)/ MYVI+'!],^6,GP:1C%# ?JH M)DB.\XZ0R?84H7D1&J9*ED>>8UP=N#?G&C;BW*&Q\:D2Z JXB]N-=M/14[$= M.1)Q6;'^N&5GM?^N$)TY$KJ^=CPC=-T3)H*G-OE6#7)GU%PD6.A1M=O]%GHW M]X*RYYG13:1E=\=#'92L[Q3N$IY5MZBZ+7TCB94)_6]CPE=U^@%%4EY/1HK' M#Z<+4N?)+N=JD?^#*&+U,V0SKG*2+,[D8=-C ;;%UKQY$Z)BLKOM2) MZKQ\=OMA='^:8D%BQ,[QG$NBD%B.9IJ1?(_3\?/LN:&U*=54J$GT];G^G>2V M=YI29PB+2M?P= ;P-.4LYV(UI>1=A0*M./1GA3WV[V ?'*^TS6Z)^," 13X MF^O;.*%:Y]]-9GL65Y]R+#$Q7%(TK5=W!P*4MQ> OK7D? E\CF4LR-S$W*#S M%M+;R/T5##EE+$/T5D_P MHL&';210_E\"DK^.JB?5_\J04%C0)43X"ABH_:\!:6\A[.O*12"FKV=U[!#] MJVB@ ;\%9("-LB<'1C-,J;E]CACH'*C# UWX/2 7[+0#\.'BT5PJZ&D);L5& M$: ;?P3J1H6\)T-N=,;-$WUU( !65,! $UX%9(*%L%?Y+U@"%7\-!:=AP6F_ MP]:3\I=$QH@6$5WJ8PWW^6O@4 ="R(0;67MUX1^,!-B##3#4@1"2XP;&>]9_ MD FQ%8QS"+*CH0Z$D!8W<=ZS!1=,$;4T"SL^9):;R!I614$E#R$5MG'T(G5Y M.X0ILWS%)?H9&X>82I8J':AY#ONOEZ$?\.+8:)9D FI%@MUNR!M0C4BA"271![+XX, M6*@%X:33+M[[OF5:= -S9\6V@FL' I4[ MA RZEMV^%3:&"XSLG7L; =4WA+2XCMN>Y;WBYM'/C#/G#>.^ M!VVS-4Y:QXF-K\'+"@,0M\)JSZI^%D3I",RZ](RM[BM9'AE:H%"U0TA*G6SW MK/R(4Q(31=CTO;X4%031>MGK<%#-0TA![3SW+/B-P,9XK"_W\]5T9J.MN)Y, M;*.V"P\U((0,M)FW7R.&4F98O-2.FE)04T)(1J$:['M0PG&FQ\AEKS^^,WO) M+4-2!065/H1$U,9QSU)_X'<"F5=;C);IF%/[7J%:(%3P$-).!],]:[X51[W: M.Q"HSB'DF[7L/ T@%XMXAM@4VY>%U".A>H>0?[JX>ANWIZ!Q>_K"<3N$/-3& MT9/4Q=I_?;Y=CRF9(OL>1&"^A%"9@O5P,O3C<^8TG>,/[$1 M1I(SG!0IANL!A[4(U)00LET0>R^.?.(T8^8%'/F+YRQGB 4*=2"$U-;)UL]R MV6*5^GK>*EZRYS+ 5@+J0PAY+H2[IT6#"IL7EY%'?(X46D7HLL-6 FI'"%DP MA+NW[1)BH">M*7>O/M@!0L4/(35V,/6B^2A%E)YE4H0CIL8.I M%\TO4BRF>@1\*_B3FJWV#+NTMQ2 >A!"S@Q@[L>+Q?/+#(J=DTXC:M#@%VB$ MXX*5LZ_WQL2Q6:%27!2P! F+"2X\U(80\N=FWGLVXEK-L-B\,LN#,>&[5I,T MEX*:$D(2#=7 SS2]\78)YRR]A8/*'TZZ7,?3S_:Z;$Q)?$DYWJ&_/#_/$'?>0_4$L#!!0 ( "6 MEE<"J4"MN1T $F. 2 =&TR,S,S-C(R9#%?.&LN:'1M[3UI4^-(LM^) MX#_4\[[=@&U\:XI-PDG)^:FAX:XX[Q!NO MY]7+1%,_M>F::NJ'3;EP5DO%C+K M#A41QDTV@>YP3G@!/4KEL*''NC.'7<_#V[!A(+(]2MVH<9>*CFRH7R1&A6>> M8S&1VEJ^230W?2_KCUPFTD&!UWE\C7U*V4(YAA;#"6S?&Z6O5;],3"4\?QHH M>)AHM-LZ;4>M[JAA<)\9_9SAY((;V;!8*A4RDC,9->$OP7^V?>Y;;&<[K_[" MVP'S*<%ALNPVX'>?,W7']IGM9R]@-1EBJ&^?,SX;^GG%P'GLE]?#;O]/-DOV M.;/,*FDS?XN3:SR*ESE"X9:W8UZO:;[VN85 ^J$)<#_:P-FF_"OOV_1WE676H*]9*A* M;*B&#?LQJL-8'K6:MLF&1VQT50!A6"E5BI6U%XR[4;IJGUU=J''_N\=75 M($(^>\DX>PC+N1ZK/ 72S,$[CCDBPA]9['.F"_Q1)<6"ZY,+/H FI^R>M)P! MM5?4@Q4 P.-=R8DFOPO[F5P YD=58CLVDR_YL(HLQ3SD5?F-FR:S)>?B5VAX M"OO@<4,QY=!OH5RLB;,N4G*V""(=E+,-*X7A&:\FZ#.S(PET.Y\8Z?6#IU)L M9F=,LF^D75'M2S74\6R1#25';BC,C'Z-PO]S1G!@ M**9$I)XJ.;B:3CB!%\X&S22A534ZY-(GT!&*[[ IDPB(GD;/N<8'\X@$GZ7J M]'KS*+E3DYW'T^53Y].SN8!3QYR& @PKS]\#L;(S7D(XTOC=5#>@UAF=PC>3 M8"4 "!]J-,[&[;[G#,9SC#]=&8'PG<%53=(*M4%V.H(#O",E(DZ8(J^?M!=C M]+(>-6^PKE3#U'6^:]%Z @TD8TT:-3;K';&? [:>F?1HOD_.F#1R^3V!A"J': M*HC9 ,HD"8V_[3STA[_XOVWWI8;F%AE0K\?M*L&F8#IL=\#=PW_=G7<:,69L MMP*+9<]I3WI"<7OWGIM^'V-%Q/%AVUG?<*MFUJ'%#2C"+<"QN;A'] MLN/XH)C#]\7Q>UQ"5O 'L.WA:6;G7_\HKA>V% +U?V/ Y1/0S0\9X:R/(+GR MPG&W",J0++5X#QX9(/]0=:5_4+AIM\C%SMAOURU;SH@D3UD[W M2.-[_:!V^J5!ZF!YX(J.T3WX&.!GJE:KW%,G$\4EQ;,I<_"!2G2_P^0R@"C_L?4#8/F8#9>,].*@#. )+;O%!4!'"SP>SR=+^ #1PRBH;29\ MPNY@$N+)U\QT]Q?.Z0O8F85 MD/NC=7[8?Z6<39L+G.U:JWEZ<7#9)KO- MLXN#1JMVWKB\:-;;Y/RX_A&2>";.EAI#"@("%X!LX$6 $RJ(<)F!CJ5)..#5 M%XL+(%. +;PYB[5)$I&#^K1C,0#5L@ =ALQ J;QNTM-,_S^XHECMFEDZU8PL1BE9D] MZKF>S74G1] SP,CL-NV=1VR3X[S=JH9?V"(OHC[[YQOU8G>M^;";V ],R M*F*=COS1;KWO"_^B1-\F>,;S8*2HF%TME-JU>][WZO5<;Y@ EXDWBP?9E6V0*:-8@F)G5/' M)S470UHHER*\I6(2_N.]3("$G]Y/SDLN0[/4 4/1(]=@)PJ32Z-U+,O?%P;0 M+SS.^,OAQ$GR>W]<8-"2"_&!2T>^)(IJ?]JJF[E6KITCC8%K.2,,U'[,TI.< M2TZ=7!(#8V;)2Y6_\T[FSA8J=\>KDOL^1VOX>;&1>CTMDW_WB_\B9%D3(AF*G4X^!3!(+LR5G\!>*1U[C2_-C8/BS9=R9\[(*V5V+C%BOIXM3N6A-:)6IN(_^T\LHIR^ M"'[_?71ME_YH7Y;GO H8[P?#W0^XA18V:05(!6#AF:0&?G$P55(0K@T#V3^# M#NII**S#QS/OPKFWTQ%X:C\T1R>#XN;H9AX('$^7V3F@WCUX*"MDCYN&X\]" MU^0R]M*6<>X(GUH_N#O;9B^)U _[0%S ;WU+;D39E9N?L>[%("GO[OQ3K MKZ=NN7(?TK&T9PSN!HWCP[NO+S.N)ST;[= @[M*&!NX =DRU_#(@_4Q?7 M-$DA)]<\1F 0$77 MNN,,28=9SCVN&5\B9A1 E>P1Z7(++2HN@"9]9IO,7%SP'4#*(+!\:C,G$-:( M"'"21'3@>F5[Z3SO+$@K0!# 38MD?ANZYC 0C8#T-P''U<47T_#/^. M05H]>&G5'2:+"@I85?#:&-9DMVR7#K@UJI)OJ/_A7Y&9&;/]YG$?: +#$H&M M'661+M2MNY*WOW%KC$3WUV9HI[)-_GA%'?#6. M-7RPSCB Q(VE8;'H0Y'H:FE-<\=$8A3SH4O%#5+?;Y%2N9"#ABB'TJ)W\PM( M_,TX&Q0UZ MOE6<;IY%A_%N O+T MBM.)]AU6/]9;:Z$+I>3*J%CJ2 I,U5/A$3=H/NM(V)4^49G-/GZH\.KA]K!T M4SXYJ!U^>SP+^\:CFW$7;6*-F9VP+QEW)FU](.AQ;?@< IZ];=,53L@OT%1&+69.B9[]=!J7)\,8,^#]N/UMJ\X=ORHZ#OS ,\H[]0! MR!6BCC9:Y(Y: 2-HW)6W"CFLD"RM$1>/)&/#?\]#,+YD4T,K\[4R(=;_?4K, MDN5D'Y-Z:MHF.D6,=$;$D&DHZ'4#,#!9U3F1'>*" ($#;>+ /=+SG'N_O[@ MSI6+*2,JB,FZ8/+(^G[TJ\#F6B/39XG&1XC*9 D7NJ$SFS)^'G:!V4!4N/)X M@..I\8#LLJ64$4.ILK@0.YXT,38Z;./NL=%SOV[&,+/32&*;:&0G\L%OB3.H M6I-PEB]RDKJ:(SW$P/[LKIZUZ;4HKK\UQ.![ 9NN>TF%16*V5'@RN/"K;N0L M_NNF<%2XQUAND,J>?#)ON[C0!^9C%GCLP'RV(_WW0##9#.:5^6$B[V#C,O.K M+A_ /9&362.<_9[#W,C(-BP)WGCLC@OH!RQ-;0-#_=20-4O8&"_ ,ZEG"I48 M-F/! YF(GCC N$2CZ$$\G))[,QVO)>EX>!$M4IU62R?BRFG=_?-A_]0_*\T] M3C8+DN?&QWXS$O[W;-\'^H](!R@0Z<,V@$2 CE.:+RZTF,&XZXL<::"3/'-( M+/2 @4$E"X)U.4M%U UQ R1'L&P%"=M7CL(*Z02@$FQKA%H)-M=6E*G('0G2 M BZ2E1%=H%P,;\U>$'2;9;+FY)M'^D:@*^;EO;YD4P^7CC5S23MJ<4&>6((E M=Q@"%PO2S4Q#:YVZ@IJ8#B33KR1">I0(YE(/)4I8[B11$9F/TI4@!H^T! MFJW\TOK[O2ZZB%UDD7K11>PBC%_AHHL)J5UZUGFL5-'M'^UQ<6B:@Z/K* J< MN! /W (N>(=;,'*5J.-7;ZK+?L5=UO Y2N,*S:,>G<3!// MS(M0U$R*N(HE]'_TD[#'NDS%1&N(019GF/#JF:GI/49OLAT&,AE@="7,\2G7 M4V9$,%XZ99R&W^N>EG%5\?P%16<';\4$%[10!#6(-=]8VH=".RP$ :D+MAB7 M)=:UGL>DR,[]EC6/9ZA")JX/6"$S#PPM+KB609908V!U+C@"]= /@F_%K>45 MJ4WJ?;R5V0(_&J YH:@OA3SUVS;ZCD4]$:J=2YO+:ZE]6>AX-I1'4I;TT.KK MBAX:]&9/><-H,"@U6 \-]!A Y]3S;1@SA$C.JQK#XJ7F0ZNDX8(M- )=.ZA M*F:FC77T3=MV[G1R,@2CWCAO1H/)((1TK"5%[(,-(*N0(S)(($>_'A-)-$[< M&E#I!YP&EF99H2%/NKHW8"9PL>'_EE=S%0*FN(6K@ P.+ M>UM,N%Q>TP7&QL@VP;I@$99.&JUVM%6((%7IJA6P<253BVS).B M:43O@.#E1AA]#@LG:A\LI'%L!.L>X#V^/FA';5CZP+&6!$B:RM ^W(MTS&FC M$Q2MX3$_PN$W!]S1<] G(&]#RB>#P ^H!?;V&&B-$"!X.1@:B$ M (.D)O@[ M/QLN5>#HA^!/,QRTD%OC]D>)NO%.2]D-8CR.M01CP%[C_DBTK0 E=Y! 0X;3 MFQLREL$\'W@EMK.QXPEHZ0>& :*E&UCD'(9EI-DD!FPYQDO!-T(XDNQ)?<)] M)0E@I4$7-C_P\'8;3Y%@["%>I0"3W<'$NI8<1@.B-$<$71Q/'@%",W8%;"-B M.H*)V&22(("(*8A"H!*3R0/$*AI!)V&$%D$OK0O M<'@4!3FR!_X$( [73#P9)9B84E93[\\A7("+KP3H]80M;(HH..$+DQ4. ][ M% >+2*C009-X9']LXWK*%<.A;18N'] Z<)F6 MOY-K>V]*_1A^B%]S]8C\T_NSN" I$H0.[HASCR*QSUW$"??5X0<+XUX!E0H, M'$[4Z?>XVS*X!784["+N:]]S@EX?D"J']Y$VM#60 L$$[TEO74CZD_HRF"V] M51P@I"X)O"0O@$D&U](A1F:R?14AP4L50(>P/K6Z(8CA>(D0!N)&QS!BDEJZ M-NIJ=C,4O"DK!++'HZ72P88_P% ]C@HEK.M5AA.P,L3D_$WF$8+R;0%A7HJ1;%%]P\#&&/E M]A%LYV1EG]$3=9GA(ST&J4E?O M]'6/N&UAH8L3$@MP02!E B!):7R=C)"W*TN]E^(;1O9^H]M%D0(6!EY"%QKO MRJC5>E/&=%&* 1!5LL27=1I$.A&QEI<:Y\L%0O;(G!W_/YV'O^BQZK<8HSJAN?_N"=4^2S0 M"!I;A$&;'!3+2F;MB2U/_&%88B!T2Z0;8ZT)0N%GEF'V;#] M3EDGN.39CT9H A<%_7.N5T,N!+M4G "%NIW$9 M(4$7%6%'"O#0Z<;1-G1#S%(#5RGAH"19%X7>VM,R+ZEB5F ,J<#B 0RI?G&G M5'(]3D[QF%Q"OT7A-/\>WHVR72?PR%)I=9E(HTR$\T@!.1EX29=5TB_O,'6& MU;48DD_(K@DAO+C0X)*0M<&)IKN479C+0U<(+Z-G,V89GP&77K]PK#OIQ&KG MUQL?!41W%12==CK4S7"(LI$.+X 'A<4)A@PAH!'!95 4D8'H7EI=6P9;4W 9 M$S7I2(8TDHYV"*P.L]%P12M$2DN.DRV5"T^- SR5' BQD2//,,64RD(%AMHF MLFI48 R]?B"D^-C*=8S'9KAV(DVFVF%,3N(GX3ZAR+M#5$NM'Z%8T"[S0:-[ MD;$ SJK!=7H*Q)) :QSDJ40( XQ@+(7C81V!3V!%99_70ETRA2SX"XE@T4V8%!G"["V@0J,^2JTJ7V6/O'S$"@9 M( Q'C'F%JT!J<0,K FVL%]@BVWPGK++9SO,=Q4V2AA *TR% C;Z#:ASF[U&; M/T1&I?QA/E"U:-WV*>@=N>?ZND*5HV!&7T7<#.I2F3?E?V%_*WWFYZ172W^G M5]\CO?IJ^IC\E9/485Z=![V0MY^ F'60:TT&\IV[HLB43@EB6?D?L=FS,^8'-"?JL@[:B_B$X["R]23I622J1 M%P: 0))K[3I18:/,_*C,9GQK:<*):S?J8R-?%?P.^[S#_0D_)TKBU6P;G6-] M WY80%0LX"4UVH/I@E:")GBS/-%WU40>?KFH//Q?NXI')^.^J(N?T] ML@>+LQS\M9^/2L7/E] 3J?ABF(I/VB)@/:!3>PV\X&/F0J"?;3%,*ZE8D%:* M2&#*)\;# 69(4PB*JT.=&+RG?"!BB>-88B3,0D9YX$:K#9SB@5UUQ[U Y,(D M8PV>NI')G@ I]-QL+OH(-I:6*0K>W,P5%1E#BWK@>:@6)PBWDCWZ"%*5/ MN$TH :38TRG J BP\D0%H,PG3)8 *D$5;[:\$MU!?<\%F\S;6#PR:-1\8#<) M!<**-.;4.GA\&>,[I66\'N.Q5U1? $?HN+>WHA'SRLL),9_IT^0J&5)@K M?RR!#251XR5>84!]<0$FU%$?@\3!4BI!0?4.U/LNURF.I>JFE*K[49EY5(ZJ MHCV:(,4O7NF4V<'?YPF!_9W/QT>'X*=/2J5>I[%-B?J!6W]0*I?+ZZ626;QB MP\W-;#'7]P<1,/)*?)!['C4 *&U6I-V3$;\" L505$Y)9QP,FW5*_UTA.Y=* MIZ64S@HQI<"84J6Y2> ?/[>8CN!'X2@65A\]-3<3.8^.*G_E6_I I(G%9S0* MB5$BKY]?PG6:YCB2@]*L:6-5$9&_%F[JGPU:SKW__1@)$37!,(^X=.6_7;KW MJ9C]J)M*V\TOI[6+RU;CMS2])\.-B43%,T](J.Q [)0FAB7- .P&@P9"%KYP MH2](U9XG!JU4/@+=3%UHHFT9:GP-I)XK_- #EX78G\#:\MTMR3'ZX*E=TKF?Z5EV*KM7VS?W;_4/NC=?GIC[/54<6SG(W[.MUHW.[6W:/>T?[ET>VWX^O#_?J0 M7SRT2O6'0MNOM(;[!]\/1J?'S4]!/G]>.#X9-AUVT31..AMF=T=?^^W-+WN%\LGH:[EA])UV]UJT MB[7;R\M@?^.F?OB'O[;W(RB.:G3S\,"X/^ZX/;/6I7YGM[_N6[W"P3UK;'36 M^\.''\:ZN][JTB_?FZ/.J'CPJ?]U='MPN.&ZQY\.[QZ&EU_;@]&W'^Z)=\C/ M\E]W'S:;#5$^,)T_UXRN]X-]OQCC]<&W/_+YQGWOVY>;[MKWM[/[=C0\Q$_% M_^V>'YT?C_9VG[B?^/:)_WIW_\/A/]39^3^.1W][,$F3\J7:VLQ*=6YC4ZCW MYDJ=IK%.>NZ#GCHSN9T\P(MX]:1^+];YU"8OU>:#O8?)N,A>[3XY67FD-)_+ MOH[L%(_E=CHK7ZG66[O[>Z//,SNVI7KQ8F-K]\G^WO4AOF&6;]U :W(\R@4< MO7NCSDX/L-!XL+V]_70P"+?^VWQ^\:*_9>/IYN;6QJ_9]($:'I__[<&#-8O[ MPS/?_E;V]_AHIO,R,7DQLYG2-BY4F2H=7NHD,.I2!X%-C-)3;9.B5.]&IV6D# M'=5NA!%>J;9?_5H5I9W,Z9V[YX?U:WZXS8W!CDUHNN>'>S=]O3Q>9"8E7GC] MX?UY>YO]B8YM-'^ISN;Q.(T@M]B&85I"R:<(/]G5NDW)6%=W.ON5[L.;0EOY;OE^H+#>7 M-JV*: YKCF-;EB;DM^7,J(^)A0 +6\XYR8?/DS27[T)S::(4/I*$JBC3X"*S M$3Q#Y4:'<_Q9F/S2\!43FWQJDF N[M+MU$X4X$T;ZM+TU*?SD_[.YN:&2( @ M>WXJNOB_J4*_6T@]_=4$)>RVG"W4I*@E"G6=X+N=JH"/E% ]-'0P&X8?/F^I M+-(EOHW_G\CO:****@A,44RJB 9],M.%44?PB]SJ"(A1SFP!L48193R%+1:U MB74[!0:S$P@C*6'N97JE05I%H1H;E>O, MAG@M-%F4SJ$"NI,*(IM0NFY^59BRI$_B.TR=I0D6QT,$JQX7)>;%0]U.6I5C M^,K%DM+P!\'SCAX@-YC,AU]>?S@][-%@:94_8>]A&O<43IL-MX+ZS%&/WAQ_ MV!]U.^]'/Y_]?'0Z>JSZ_673!^1 R*:"N0*7HD ]>C\\.QS^_:7:/WU_]KBG M:.@FAPX^$4=*$\SX&'2>AAK*2Y*TPE$=0MQ+_D4H.TBQ=$$^#*)&4*6);=#M MG.0&I[X)$QK*$4:XU'RJ4(^(MH_%$&Z"PAY) K5-,-5%V2]S'5S(XQXA8Y.4 M?%ZK:\BG+I+T"A;4,D^NC"\3DO$B%XMWW\%+@*XC3*!.85,V=[9Z-D_"/(V- M>D1L?=R35]-):;!%7<(60UL8.D>@ 1PPX;D\L(F>Z,Z9:055 MR,KD%:.*.0 NQE?P$X@\X!:#&=:+,6PR@59Y7-6[@[GJJDSE72BG)PH+R-CR MC;M+QV[PIG-1?FVY$>$$E@L[["TKB;OT-@BNFIO^&)+ ?&M6NM]T:PA^JFA MYE2I+WBLB\G4!CR!S2FC\VB^9.0E-%1-9PZ/NQT \C(R%IRRI^Q$IFU0^]I# MN6D!?$_!!;#M=*U/)9X(V:FX+ 99XA];>*C; 2/L;>+ =6".D?X DG-R\4CG MRBTH5RTDOV>V]C *?ZO25P<+)##T?,@_382[<==Q"M"I2.'*-;Y'I1M=%O+H M59KCG)S UK". CA2/LP+SE"H2TLX*F<:5FT4;(MJ%61NH4=L0I%^:"8@C+(6 M'VG)B<[0S 8XIYWA:>J/"WV8A+J8O1(;[3W,94^JT#94A[DZM0'L/U1O=1G, MH,^>.%.SKH.9-1,U^FP"N <(ZX<)N %P0WG9_(PE=CMN>N>5/6Y /!.QQZR) M#8O $J_QM@*GAC^5NJ'FE$T+;I5C0<1]K:YF:62<,^I2GBPTT*Z$,C%!!!S, MU:R"@N&?]:HAE[&-Z+ P9L<5]*&E\U]M5-"X\&' M3T>'_:T7W0Y S&VNF*57<.#*V6"06X=S-L[2O!3=0 4>N@KZ<@$UT-IDG)E)LTBPT-P&0H,B..R_ZO9CAK%A-G&-$QA'MCWM]*4'F>F/Z5GKDO!EMXS^.DQ6#21_TI]_-Y<@EC#S.@6%!0C2S5J9LFNL8FKFBO&A?E-+I MT;N1CR/=C-2[Q808]1!>'^-@=C[AX]Y1E:>9 8"](]&4DV?H4I./1N^&C^\? M@1?8(28C5+DD/N>MY$!-UA,?_7<[8Y>#[1^DGWJ,=EJ4U#%S2'=B<^HE=&36 M!4:#S:T!?[8-;D,=E6*^/K40IW+80;B#WE-:-CGK8@UBO)@B OC"$0?/'!KG M%B(H+$D:P-S-[1+&H;-HZR;!8F&%?4EJT+)S9D]@-(M9MW> W3G\L21!H2QX M^N+5.6*-)%WX:D,ZTAP'BU27#@CS#;*A(4:D*<+ EH+!!A%'S>M#]_I) M"ON9$_X\^'4[A8/'FO38VG7TI;:1O$M:T:(_5S/CNW<8T,0 M8)XJJ,#O;"1QG0_E>DQ5 _\BKHK)C58DF.DYO'*RNJRO),N%9KI,4Y6141)N MY91P&/ZU' N?\1F6;L>E6-S1"C;Z3^?,V_*8^/!#%HREIX(, MG-8XE)-BPER6C%CS#:;XF>O/L(*2T#EU'\)\JPDH+NA:WAB5D9&Q#<)$E%[U M19.Q<-<^\$LRE#6B"0+5*B#59[* 45AHELUC=2"U.A(ADYEL@!=!; 8*ST41 M\%Q2H9!X8+%D"C&+X"!;FPT>WETD:'4$_%N_KUY;$X4OU6D%49R0*?3[>[N' M1Y^6.QE<"7@[*Z\5@>4S7Y4:[+ *W'I9ZD^%_=U@G7QN#% QN1ML/V+2'A^K M HX>+O:)]_?\GZT%/EE:X6U+XCO!Z^[9QY.]K=TG_*&&7W'J;L='>M.<].RW MBKE.!\>K[SF7IULL AXP@G5N?N\LD2I^A>=_JYC1P;!.W](:=(-=;@W6&.;3 MEL'5GUVSN34=.UG9WJ@SQ.O3"S[VQP8ZP!HS67-[24_7K(C+_-].V?: 6S;^ M/X=AL,4G+5T-8(1#(,WO>,O.S?M O.(#H,-% '0O-W-8F18[:[C8 DR8L6T7 M[<%YPI!%_3HS5"4Q.7Z=C9(R@(OW("0)4=($W"S&]S7%6919);)L2E?\K&&! MUP+,%O]#A.J^-LE,2[9W=>B5E%W35\GF:EC6WA\E"(<$W>A.1Y.H;D58A(BCD/ MW8SQ%R9I$S.QIH!J0)&Q$&.\=AOLO.%;3 MKO2Q,/?2HJMT1%" MHX4DH.(C9DZ3^LP_2%E<3_!Z$$DZ?SQ7/[_]T%.2#,[<,#,WS*+_2\RM&0./ M-I2[@.F;9C1)5$@%,G@VN1Y.YNI98\N@ MD+THR]6 1:VYJ9H*[-95O;K.[<+^>1W=NO2"]?&<9LN95!#JS.:?8:3?0<4\ M-?TY8\)UDF5;CMK>7-/.633MT3Q)H/XT9^30U$P>QE*M/YC9BRJ95LE<*U]= M'(W32*M/DH\\=.T%/76,HZ9YXH8^J&ZG:81:*E>^MYF>U>^>VDFI/D%#4-YK M9DO=%RZ3/G19T?[ KTY2CX3$"%$1#V))C^=R@/J2J6M*&>-8EI*0JQ]9AD[M MO&IM@76]P;42UM6F6E*^.'2I$24Q%XEIFOJ!9D4,=H6?URJRS+4PB[769+N= MAD.YA(3SL]\=%7"5AZ+N)'9YF36*EO3-(BE35T.*=@_PPLW\?KSVU"_J$89D M*9C.X[-)5>+:WF0'?TK2_3LY"&@EPMIQY9./.-LJEARXS44W" XS'K6>8&)0 MFP11%=;4,75)NVR?#I,-HR3_J>P>^Q.-[3MI= 3YU3K-V5L]GO>]X[2"F MI\6VZSE1L<8RH.*Y-% R><1"6)XZ/!,R&:5C218LDG2UI?9JQ*CWM@H9TE/4 MZ@MHN'Y$,HSE\^4)@N&T6 9O;U4++^U)O4/X;*OH.N:YX]IW?2@0 A(*-A[B M[W[E(X![&G^0]EF;QQ:&O_3:&[2)A>/(Z2:&S@:17$VTS1TE7I-?7JWX M-3Y/6_$C4*Y-I.!JX4I>^G[RS2[1_W M)A!*GXTIM#K7ESO8' SZ^.,I>Z(_[M5W<$*$:5KJ_!&S5&$5"#\4,X!L8U8= M'0?P8"KM!Y!F#8<^EO%("<,_\.;MZYRR &#^TA*G*7NURU2*L])(SD>E.8N- MD4D;!0L]P7EE)A-W#O2\*3%^6Y"$:T;-/IJFARX5$3.=C@!MCC4.@YDUE\ZA MV)6K'D:R,HB.#QWB(1R*0H@H++_NMN&)4YAXG.M@T0#\YID(X\V =7 YD:;6 M=RVX;@<-0)G.Q).#6=U#1;S#HJ5]1:\V-"B7?V)9@]2HR)A/=$TODM+6M6?5 M^KC#]/W!WB=;8"/LP(*DH:)"TFHB8IFJ#O(C$IY259DPGPWU.HVB]$KQMLVE MU7SY1]I3K74.T)-/#_-3WY'(STKY\-@F%R8\2MQ35! ^? V]C=/T@A_>:9%] M2_YT\*_\Z;W(G[9"U1MO9]S+^'7UGH/Z^C4'\OGO?L]!?=,U!\#N3?<)3&IAWIZ&+ MR]X/3UY=NYSB^:]T,2'(\7-R<1/)1KCR]5)$&N1I066'TEC HG0RK3O<&ZUI MX$";H+^4I/0VF\5(#6[6Q.J@-TBWF^8YLMC!L4NNWDM;?(OAF)E!#2#:G(" I MN'1IO(N\HD6YSKNM+2=8<)2F0.D>^M;M'[BG5_9^L&[O:GGKD'X_-^0-O*SC MG7=M3ZZ20"9IWRPPGS/>Y&1>I+;D)F82AYFD025MD(U7M(,PP 9.8F8KTL*Z MIA0)SVN PY*96)@*D_8W(WW@(A1TN5G*(XWLZJN7LEI8Y2L@$K+I=FD' 2K6 M$92^%],*N\_GO-[=;4072(@9R58CO]6BV6JW MX_J<^.FR>&AO/AD1&YVTKMBV[E10IT;<+'3 MDQLXF"YDS6W1M.2PAX';F(T0BU9([1N^$46QP\%/>\4K>'6;?*SG3?.]_XCM M/ZN?,=A<_G]=E?KM6([]6 M %%]I'.BGI1[I3K $I"4:H&[DF]?L:%N9V%$M:%13>Q(<9J<"S&BTB3Y59@O MF*$G \!;FAWY,%,-I0<>OS#F(8!<$4UDO06[V\<"L@VZ^_B9D!Z4=>V#=E'4 M]=Z"WUS+&"[(15.N7;2U-]7G!JNEZ=TUS@V3^9>WZJ_9+?DJ>RR;#OEE3X06 MP9CY>94LDHO[YSCW%RRYB41+Z$16 M_PWK9C%'1F'#1.MRDL_E!B#,);"SV_$I*U+2-):;G;6JYFVW!.7)JZQI_AXD6L)E>JL?OO+HR+7QOT*BC?Z=^W+I:[^ MXQHSECOTUV]Y8MD,72Q^ T+K9.1XH\].9,2FNJS*@DU]C)R-#OSY\;BU71R) M$-TP2>AQIT9Z4? B:$OLSH:MS?Y/#1!).V)4[&=ONET(,>J*)OU>(+^7W M.K@1BVM#_MW]JIEJ7$@Z"79R?7NC@]5?90!X<'J9IY4<&>R3EDM?L(&*7;^( M1"2_F7S%Y6N& %1F-W+B+O#6!8W09Y_G F[L]%U=B0<:=D+;(H@DK\T9TW%4 M4Q2N3,BE%!V47;*5A\\*^VBAD%S_G43 41K(W'L #6()@%.Y$N/ L2>7 M@&SS16#SH(J+TC4Q\5*VN\2U9C8ZZ-B?!M+JT8"PEJ2W"R8B>P&9SM(T=-][ M:*X!69JA/22W8+@PTCDEH83+XM^HB+O.YEW>;/4Z\-=N ]_;5J,OW'NNDT>+ M_0H;6=Q)T^UJ>OW2EVNM"SGV<9CJT@C[^OR^[%N M_$T%4N&X G[Z6V:+Y6)%,,9R42=9++S!U/?59,(<+M",;2]U<;.^4;;!.'11 M/;@R8_Q5"@=-0K\N$=#9?E&/ZE]H@\5<\2)+_OCNAZS?D.K?_E>J__ZD^FF] MVG':X$]+,_PS"]X]VG,]=$=[M[S:T4LZJ1S5/P8FLQN)>&]YBU.$' M]6S[^3.UN;,SV/KA[DO["V6@6U>!F_%(^I+ ,@Z\6;[\;E/5 Q_,P*V! ]A> MM_-N0QWH2(]Y0MWBC.\8-)/0'-I<+IC?XMC'=F)P"JMA",8HEQMN;>B_;JD7 M6\_Z3Y]O]G>>;CZ_Q9&#H);RCQ'67P16^^6[].W=]8R?V)F!^"P/$W.;:KR_ M)O(4)C)XOHW_[SR]Q9$OID[&]\U '+HL':[? \2&59AK]3JW]C;5>:9CM9^G M5TG/R>4HN=66'0\H.ULO^B]VGCV[Q9$UQ3&A-'XL=#SF%NZ'H?@,\?7S M[C]3%B]UX@@VPM8\N<6YCDZ=G![J.'NE3DZ5X-JM(N476,FMS6'S'Z_7%.^Z M*:W/,'P/>/]U1@^>; M.X/;I",W*:1Y[-O"WQ]>J0\N(_R2;=CEW8F&OQZ:MK:Z(HTG_*\>R"\KEO]: MPO\ 4$L! A0#% @ )8"65X!+OC"V P ]PT !$ ( ! M &)R;G,M,C R,S$R,C N>'-D4$L! A0#% @ )8"65_HZ:;SL" MM&D !4 ( !Y0, &)R;G,M,C R,S$R,C!?9&5F+GAM;%!+ M 0(4 Q0 ( "6 EE>E>P4O!PP #>1 5 " 00- !B M&UL4$L! M A0#% @ )8"65P*I0*VY'0 28X !( ( !M"$ '1M M,C,S,S8R,F0Q7SAK+FAT;5!+ 0(4 Q0 ( "6 EE=M;A LG1@ #1A 6 M " 9T_ !T;3(S,S,V,C)D,5]E>#DY+3$N:'1M4$L%!@ 0 & 8 C $ &Y8 $! end